These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1470 related articles for article (PubMed ID: 26638176)

  • 1. Surface modification of PLGA nanoparticles with biotinylated chitosan for the sustained in vitro release and the enhanced cytotoxicity of epirubicin.
    Chen H; Xie LQ; Qin J; Jia Y; Cai X; Nan W; Yang W; Lv F; Zhang QQ
    Colloids Surf B Biointerfaces; 2016 Feb; 138():1-9. PubMed ID: 26638176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chitosan-modified PLGA nanoparticles tagged with 5TR1 aptamer for in vivo tumor-targeted drug delivery.
    Taghavi S; Ramezani M; Alibolandi M; Abnous K; Taghdisi SM
    Cancer Lett; 2017 Aug; 400():1-8. PubMed ID: 28412238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biodegradable polymeric nanoparticles for oral delivery of epirubicin: In vitro, ex vivo, and in vivo investigations.
    Tariq M; Alam MA; Singh AT; Iqbal Z; Panda AK; Talegaonkar S
    Colloids Surf B Biointerfaces; 2015 Apr; 128():448-456. PubMed ID: 25769281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer.
    Sun B; Ranganathan B; Feng SS
    Biomaterials; 2008 Feb; 29(4):475-86. PubMed ID: 17953985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved mucoadhesion and cell uptake of chitosan and chitosan oligosaccharide surface-modified polymer nanoparticles for mucosal delivery of proteins.
    Dyawanapelly S; Koli U; Dharamdasani V; Jain R; Dandekar P
    Drug Deliv Transl Res; 2016 Aug; 6(4):365-79. PubMed ID: 27106502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel-loaded nanoparticles based on star-shaped mannitol-core PLGA-TPGS diblock copolymer for breast cancer therapy.
    Tao W; Zeng X; Liu T; Wang Z; Xiong Q; Ouyang C; Huang L; Mei L
    Acta Biomater; 2013 Nov; 9(11):8910-20. PubMed ID: 23816645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel docetaxel chitosan-coated PLGA/PCL nanoparticles with magnified cytotoxicity and bioavailability.
    Badran MM; Alomrani AH; Harisa GI; Ashour AE; Kumar A; Yassin AE
    Biomed Pharmacother; 2018 Oct; 106():1461-1468. PubMed ID: 30119220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surface decorated nanoparticles as surrogate carriers for improved transport and absorption of epirubicin across the gastrointestinal tract: Pharmacokinetic and pharmacodynamic investigations.
    Tariq M; Alam MA; Singh AT; Panda AK; Talegaonkar S
    Int J Pharm; 2016 Mar; 501(1-2):18-31. PubMed ID: 26812610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accelerating thrombolysis with chitosan-coated plasminogen activators encapsulated in poly-(lactide-co-glycolide) (PLGA) nanoparticles.
    Chung TW; Wang SS; Tsai WJ
    Biomaterials; 2008 Jan; 29(2):228-37. PubMed ID: 17953984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation and in vitro evaluation of thienorphine-loaded PLGA nanoparticles.
    Yang Y; Xie XY; Mei XG
    Drug Deliv; 2016; 23(3):787-93. PubMed ID: 24870204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surface-modified PLGA nanoparticles with chitosan for oral delivery of tolbutamide.
    Shi Y; Xue J; Jia L; Du Q; Niu J; Zhang D
    Colloids Surf B Biointerfaces; 2018 Jan; 161():67-72. PubMed ID: 29040836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: effects of surfactants on particles size, characteristics and in vitro performance.
    Liu Y; Pan J; Feng SS
    Int J Pharm; 2010 Aug; 395(1-2):243-50. PubMed ID: 20472049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation, characterization, and in vitro and in vivo investigation of chitosan-coated poly (d,l-lactide-co-glycolide) nanoparticles for intestinal delivery of exendin-4.
    Wang M; Zhang Y; Feng J; Gu T; Dong Q; Yang X; Sun Y; Wu Y; Chen Y; Kong W
    Int J Nanomedicine; 2013; 8():1141-54. PubMed ID: 23658482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocytosis-like uptake of surface-modified drug nanocarriers into giant unilamellar vesicles.
    Tahara K; Tadokoro S; Kawashima Y; Hirashima N
    Langmuir; 2012 May; 28(18):7114-8. PubMed ID: 22515197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chitosan-coated PLGA nanoparticles: a sustained drug release strategy for cell cultures.
    Chronopoulou L; Massimi M; Giardi MF; Cametti C; Devirgiliis LC; Dentini M; Palocci C
    Colloids Surf B Biointerfaces; 2013 Mar; 103():310-7. PubMed ID: 23261553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carboplatin loaded Surface modified PLGA nanoparticles: Optimization, characterization, and in vivo brain targeting studies.
    Jose S; Juna BC; Cinu TA; Jyoti H; Aleykutty NA
    Colloids Surf B Biointerfaces; 2016 Jun; 142():307-314. PubMed ID: 26970818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chitosan-modified poly(D,L-lactide-co-glycolide) nanospheres for plasmid DNA delivery and HBV gene-silencing.
    Zeng P; Xu Y; Zeng C; Ren H; Peng M
    Int J Pharm; 2011 Aug; 415(1-2):259-66. PubMed ID: 21645597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of chitosan-coated poly(lactic-co-glycolic acid) nanoparticles for improving oral absorption of 7-ethyl-10-hydroxycamptothecin.
    Guo M; Rong WT; Hou J; Wang DF; Lu Y; Wang Y; Yu SQ; Xu Q
    Nanotechnology; 2013 Jun; 24(24):245101. PubMed ID: 23702815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preparation and characterization of surface-modified PLGA-polymeric nanoparticles used to target treatment of intestinal cancer.
    Ahmad N; Alam MA; Ahmad R; Naqvi AA; Ahmad FJ
    Artif Cells Nanomed Biotechnol; 2018 Mar; 46(2):432-446. PubMed ID: 28503995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deoxycholic acid modified-carboxymethyl curdlan conjugate as a novel carrier of epirubicin: in vitro and in vivo studies.
    Gao F; Li L; Zhang H; Yang W; Chen H; Zhou J; Zhou Z; Wang Y; Cai Y; Li X; Liu L; Zhang Q
    Int J Pharm; 2010 Jun; 392(1-2):254-60. PubMed ID: 20347028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 74.